August 3rd, 2010
Building on Your Success
Harlan M. Krumholz, MD, SM
Welcome to the remodeled CardioExchange: We hope you like our new look! In our efforts to develop a website that promotes learning and discussion about our rapidly evolving field, we’ve been listening and learning.
We have many new features. Some of the most prominent are:
- You can now see all of the activity on the site from the new homepage, including newly uploaded posts and comments.
- You can now make anonymous comments. Many people think this may foster more discussion. We are eager to see whether that happens.
- You can now “follow” the people, blogs, and topics that interest you the most and receive email notifications when new activity takes place.
With all these changes, our philosophy and approach remain the same. We want to be a credible, trustworthy source of information and a venue for the exchange of views and perspectives. We want to give you access to the various ways people are thinking about new (and old) information in medicine — and provide you the opportunity to learn from each other.
And we are not done listening. We will continue to learn from what you say on and do with CardioExchange, as well as from your direct feedback. Ultimately, the site is a facilitator; it is the people who make CardioExchange. We will be encouraging you to be more involved and to try out the various features. And we ask you to bring in others to participate. The site ultimately belongs to the community — and it is up to all of us to define it.
Categories: General
Tags: CardioExchange, social media
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Descending Thoracic Aortic Aneurysm July 16, 2026A man presented with a 2-month history of chest heaviness and a 2-week history of shortness of breath. Pulsations were visible between his ribs (shown in a video). Ultrasonography revealed a rounded structure near the heart.
- Balancing the Scales — Extended DAPT in Coronary Artery Disease July 16, 2026The appropriate duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has remained the subject of a central debate in cardiovascular medicine. DAPT is intended to mitigate ischemic risk, but its maintenance warrants balancing the benefit against the concomitant risk of hemorrhage.1 Consequently, determining the appropriate...
- Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease July 16, 2026Among patients with multivessel coronary artery disease who were in stable condition 1 year after stenting, an additional year of DAPT led to a lower risk of ischemic events than aspirin alone, without increased bleeding.
- Platelet-Activating Anti–Platelet Factor 4 Disorders July 13, 2026This review summarizes platelet-activating anti–platelet factor 4 disorders, including heparin-induced thrombocytopenia and related syndromes, highlighting diagnosis, antibody mechanisms, and treatment strategies.
- Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty July 12, 2026After total hip or knee arthroplasty, aspirin alone was noninferior to rivaroxaban followed by aspirin in preventing symptomatic venous thromboembolism, with a similarly low risk of bleeding complications.
- Descending Thoracic Aortic Aneurysm July 16, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
